GlassScriptPhysician profile
Mushtaq Nabi
NPI 1386660017
$1,327.09
in general payments reported to CMS, 2019-2025
15 companies · $56.89 in 2025
The $56.89 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $194 · 2021: $328 · 2022: $20.98 · 2023: $24.07 · 2024: $270 · 2025: $56.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $351.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $345.29 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $204.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $180.40 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $124.73 | 2024 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $122.69 | 2024 | Arexvy |
| Pfizer INC. | $108.02 | 2019-2021 | |
| Alkermes, INC. | $38.94 | 2019-2025 | Lybalvi |
| Allergan, INC. | $36.02 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $34.68 | 2025 | Uzedy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.84 | 2019 | |
| Gilead Sciences, INC. | $24.07 | 2023 | Veklury |
| Alexion Pharmaceuticals, INC. | $23.92 | 2021 | |
| Taiho Oncology, INC. | $22.91 | 2024 | |
| Lundbeck LLC | $18.43 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mushtaq Nabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.